Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christof Scheid

Showing results (121-130 of 200) with videos related to

Pageof 20
Sort By:
Nature Medicine|February 21, 2025
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibodyTill Braun, Michael Rade, Maximilian Merz, et al.
Future Oncology (London, England)|January 11, 2021
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemicSrdan Verstovsek, Chih-Cheng Chen, Miklós Egyed, et al.
Transplantation and Cellular Therapy|August 28, 2022
Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic LeukemiaDietrich W Beelen, Renate Arnold, Matthias Stelljes, et al.
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Bone Marrow Transplantation|August 27, 2024
Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMTUrban Novak, Jarl E Mooyaart, Michael Daskalakis, et al.
American Journal of Hematology|June 28, 2026
Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell TransplantationXavier Poiré, Dirk-Jan Eikema, Linda Koster, et al.
Bone Marrow Transplantation|November 9, 2019
Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemiaMauricette Michallet, Peter Dreger, Mohamad Sobh, et al.
Haematologica|August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Blood|January 6, 2023
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myelomaNicola Giesen, Manik Chatterjee, Christof Scheid, et al.
Bone Marrow Transplantation|April 25, 2024
Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)Christian Niederwieser, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Pageof 20

Showing results (121-130 of 200) with videos related to

Sort By:
Pageof 20
Nature Medicine|February 21, 2025
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibodyTill Braun, Michael Rade, Maximilian Merz, et al.
Future Oncology (London, England)|January 11, 2021
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemicSrdan Verstovsek, Chih-Cheng Chen, Miklós Egyed, et al.
Transplantation and Cellular Therapy|August 28, 2022
Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic LeukemiaDietrich W Beelen, Renate Arnold, Matthias Stelljes, et al.
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Bone Marrow Transplantation|August 27, 2024
Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMTUrban Novak, Jarl E Mooyaart, Michael Daskalakis, et al.
American Journal of Hematology|June 28, 2026
Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell TransplantationXavier Poiré, Dirk-Jan Eikema, Linda Koster, et al.
Bone Marrow Transplantation|November 9, 2019
Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemiaMauricette Michallet, Peter Dreger, Mohamad Sobh, et al.
Haematologica|August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Blood|January 6, 2023
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myelomaNicola Giesen, Manik Chatterjee, Christof Scheid, et al.
Bone Marrow Transplantation|April 25, 2024
Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)Christian Niederwieser, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Pageof 20